Health Canada replaced its 26 June 2015 RMP submission guidance with a new overview guidance issued 24 February 2025 and effective 1 July 2025. In parallel, Health Canada linked the guidance to Agile Licensing-related Food and Drug Regulations provisions on RMPs that will come into force on 1 April 2027 and referenced transitional provisions for RMPs submitted before those regulations take effect.
RMPs are core pharmacovigilance risk management deliverables used in Health Canada’s review of drugs in Canada and are explicitly framed as aligned with ICH E2E in the updated overview. Any change to national submission guidance (including summary and form expectations) can affect dossier completeness, Health Canada review interactions, and governance over risk management content that connects to PV planning and risk minimization measures. The stated effective date (1 July 2025) and the separately stated regulatory in-force date (1 April 2027) create two compliance milestones that PV/RA organizations should manage, including how existing RMPs are handled under referenced transitional provisions.
1) Retrieve and review the updated “Submitting risk management plans guidance document” (PDF) and linked templates referenced from the overview (e.g., RMP note to reviewer, Canadian-specific addendum, RMP summary template) and map deltas vs the superseded 2015 approach. 2) Update Canada submission checklists/work instructions for the 1 July 2025 effective date, including the requirement that the RMP include a summary in English and French and use of the RMP summary attestation/acknowledgment form. 3) Ask Regulatory Intelligence/RA to brief PV leadership on the Agile Licensing notice timeline (RMP provisions in force 1 April 2027) and confirm how transitional provisions will be operationalized for existing RMPs submitted prior to that date.
PV Quality Lead (SOP/checklist update) with Regulatory Intelligence Lead (interpretation) and QPPV oversight; Regulatory affairs for submission implementation
Complete gap assessment and implement updates before 1 July 2025; monitor Health Canada for further transition details leading up to 1 April 2027
1) Retrieve and review the updated “Submitting risk management plans guidance document” (PDF) and linked templates referenced from the overview (e.g., RMP note to reviewer, Canadian-specific addendum, RMP summary template) and map deltas vs the superseded 2015 approach. 2) Update Canada submission checklists/work instructions for the 1 July 2025 effective date, including the requirement that the RMP include a summary in English and French and use of the RMP summary attestation/acknowledgment form. 3) Ask Regulatory Intelligence/RA to brief PV leadership on the Agile Licensing notice timeline (RMP provisions in force 1 April 2027) and confirm how transitional provisions will be operationalized for existing RMPs submitted prior to that date.
Health Canada has replaced its June 2015 risk management plan (RMP) submission guidance with an updated document, “Submitting risk management plans guidance document: Overview,” issued 24 February 2025 and effective 1 July 2025. The update is positioned as part of Health Canada’s established approach to using RMPs in the review of drugs in Canada, and it is explicitly linked to forthcoming Food and Drug Regulations provisions relating to RMPs under the Agile Licensing framework that will come into force on 1 April 2027.
For pharmacovigilance (PV), regulatory affairs (RA), and compliance teams supporting Canada, the immediate change is operational: the guidance is being replaced on a defined timeline, and sponsors/MAHs should ensure their RMP packages and submission controls align with the updated expectations before the effective date.
Health Canada’s overview states that it has adopted and integrated the use of RMPs and the ICH E2E guideline into the review of drugs in Canada. The same overview notes that amendments to the Food and Drug Regulations to incorporate this long-standing practice will come into force in April 2027. Separately, Health Canada’s Agile Licensing notice states that new Food and Drug Regulations provisions relating to RMPs will come into force on 1 April 2027 and references transitional provisions for RMPs submitted before the Agile regulations come into force.
From a PV execution standpoint, teams should pay close attention to the submission components referenced in Health Canada’s pages supporting the overview. Health Canada’s “Preparing and submitting an RMP” page states that all RMPs submitted should meet a standard acceptable to the Minister, describes standard sections of an RMP (including product overview, safety specification, pharmacovigilance plan, and risk minimization measures), and states the RMP should include a summary of the plan’s contents in both English and French.
In addition, the overview directs users to an RMP summary attestation/acknowledgment form intended to acknowledge Health Canada’s request that the summary be provided in English and French and reflect the final RMP. For organizations that run global RMP processes, this type of country-specific summary and form step can require procedural updates across document authoring, translation workflows, submission publishing, and quality control.
Two dates matter for planning. First, the new guidance has an effective date of 1 July 2025, which is the near-term control point for submission readiness. Second, Health Canada has connected RMP practice to the Agile Licensing regulatory provisions that will be in force on 1 April 2027. While the sources provided reference transitional provisions for RMPs submitted before the 2027 in-force date, the excerpts do not provide operational detail on how those transitional provisions will apply in specific scenarios; a document-level review and ongoing monitoring for further Health Canada detail will be important for organizations managing existing RMPs.
What PV teams may want to do next is structured, compliance-led work: retrieve the updated guidance PDF and linked templates referenced from the overview (including items such as the RMP note to reviewer, Canadian-specific addendum, and RMP summary template, where applicable), compare them to the superseded 2015 approach, and update internal checklists, work instructions, and training plans ahead of 1 July 2025. In parallel, Regulatory Intelligence and RA can brief PV leadership on the 1 April 2027 Agile Licensing timeline and begin planning how to handle RMP lifecycle updates for products with RMPs submitted before that date, in line with the referenced transitional provisions.
Teams supporting Canada-facing risk management should close with a practical control: confirm that the RMP summary in English and French and the RMP summary attestation/acknowledgment form are built into the end-to-end RMP submission package governance before the guidance becomes effective, and track Health Canada updates leading into April 2027.
Review and update labeling processes in accordance with the newly published safety-related changes for affected products.
MAHs must allocate resources to develop and maintain SPPs, ensuring they meet the new regulatory requirements and are ready for submission within two days upon request in crisis situations.
Implementation of new dosing schedules and an emphasis on monitoring for potential adverse reactions as outlined in the prescribing information.
Regulatory compliance processes may need updates to incorporate the new recombinant endotoxins testing method and guidelines established under the ICMRA framework.
